Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
UTHR 
United Therapeutics Corporation (UTHR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: UTHR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $379.32
1 Year Target Price $379.32
| 6 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.37% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.16B USD | Price to earnings Ratio 12.22 | 1Y Target Price 379.32 |
Price to earnings Ratio 12.22 | 1Y Target Price 379.32 | ||
Volume (30-day avg) 14 | Beta 0.57 | 52 Weeks Range 266.98 - 417.81 | Updated Date 08/15/2025 |
52 Weeks Range 266.98 - 417.81 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 25.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-29 | When Before Market | Estimate 7.35 | Actual 6.41 |
Profitability
Profit Margin 40.36% | Operating Margin (TTM) 45.64% |
Management Effectiveness
Return on Assets (TTM) 12.96% | Return on Equity (TTM) 19.3% |
Valuation
Trailing PE 12.22 | Forward PE 11.48 | Enterprise Value 10992007319 | Price to Sales(TTM) 4.6 |
Enterprise Value 10992007319 | Price to Sales(TTM) 4.6 | ||
Enterprise Value to Revenue 3.57 | Enterprise Value to EBITDA 6.36 | Shares Outstanding 45226300 | Shares Floating 41706754 |
Shares Outstanding 45226300 | Shares Floating 41706754 | ||
Percent Insiders 1.77 | Percent Institutions 99.11 |
Upturn AI SWOT
United Therapeutics Corporation
Company Overview
History and Background
United Therapeutics Corporation (UTHR) was founded in 1996 by Martine Rothblatt. It focuses on the development and commercialization of innovative therapies to address the unmet medical needs of patients with chronic and life-threatening conditions.
Core Business Areas
- Pulmonary Hypertension (PH): Developing and commercializing therapies for pulmonary hypertension, a chronic and life-threatening disease affecting the arteries of the lungs.
- Organ Transplantation: Developing technologies and therapies to increase the availability of transplantable organs and improve outcomes for transplant patients.
Leadership and Structure
Martine Rothblatt serves as Chairperson and CEO. The company has a traditional corporate structure with various departments overseeing research, development, manufacturing, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Remodulin: A prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH). Competitors include generic versions and other PAH therapies from companies like Johnson & Johnson (JNJ) and Merck (MRK). Revenue contribution is significant but declining due to generic competition.
- Tyvaso: An inhaled prostacyclin analogue for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It has significant market share in the inhaled PAH treatment space. Competitors include Adcirca (tadalafil) from Eli Lilly and Letairis (ambrisentan) from Gilead Sciences.
- Orenitram: An oral prostacyclin analogue for PAH. Competitors include other oral PAH therapies. Market share is moderate.
- Ralinepag: An oral IP receptor agonist for PAH. Ralinepag has strong potential for future growth due to its convenient oral administration and efficacy profile. Competitors include other oral PAH therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The market for pulmonary hypertension therapies is growing, driven by increased awareness and diagnosis.
Positioning
United Therapeutics is a leader in the PAH market, with a strong portfolio of prostacyclin-based therapies and a growing presence in organ transplantation. Their competitive advantage lies in their expertise in PAH and their commitment to innovation.
Total Addressable Market (TAM)
The global pulmonary hypertension market is expected to reach USD 8.1 billion by 2028. United Therapeutics is positioned to capture a significant portion of this market with its diverse product portfolio and ongoing research and development efforts.
Upturn SWOT Analysis
Strengths
- Strong product portfolio in PAH
- Expertise in prostacyclin-based therapies
- Commitment to innovation
- Proprietary technologies in organ transplantation
- Experienced management team
Weaknesses
- Reliance on prostacyclin analogues
- Exposure to generic competition
- Regulatory risks associated with drug development
- High research and development costs
- Dependence on single indication for some key products
Opportunities
- Expansion into new indications
- Development of novel therapies for PAH and other diseases
- Strategic acquisitions and partnerships
- Growth in organ transplantation market
- Geographic expansion
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Clinical trial failures
- Competition from other pharmaceutical companies
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- GILD
- BMY
Competitive Landscape
United Therapeutics faces competition from large pharmaceutical companies with diverse portfolios and smaller companies focused on specific PAH therapies. UTHR's strength lies in its PAH expertise and prostacyclin-based therapies. It has to protect itself against competitors that have similar technologies.
Major Acquisitions
SteadyMed Therapeutics
- Year: 2018
- Acquisition Price (USD millions): 216
- Strategic Rationale: Acquisition of SteadyMed and its PatchPump technology to enhance Remodulin delivery.
Growth Trajectory and Initiatives
Historical Growth: United Therapeutics has experienced growth driven by its PAH therapies.
Future Projections: Analyst estimates suggest continued growth driven by Tyvaso and Ralinepag. Consult financial news and analyst reports for detailed projections.
Recent Initiatives: Focus on expansion of Tyvaso into new indications, development of organ transplantation technologies, and strategic acquisitions.
Summary
United Therapeutics is a strong player in the pulmonary hypertension market, with a diverse product portfolio. Tyvaso is a large driver of revenue and will continue to grow, although it has some dependence on prostacyclin analogues. The company needs to manage generic competition and ensure regulatory compliance to achieve continued success and should look for expansion of the business line.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About United Therapeutics Corporation
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 1999-06-17 | Founder, Chairman & CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1305 | Website https://www.unither.com |
Full time employees 1305 | Website https://www.unither.com | ||
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.